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The primary multiplication site of VVTGgRAB, a 
recombinant vaccinia virus (VV) expressing the rabies 
virus G glycoprotein, was studied in comparison with 
that of the parental VV Copenhagen strain, after oral 
administration to foxes. Foxes were fed with 10 s 
TCID5o of either VVTGgRAB or VV and were 
sacrificed 12, 24, 48 or 96 h after inoculation. Both 
viruses were detected by viral isolation in the tonsils 
during the first 48 h after inoculation at titres between 
102 and 104.3 TCIDs0/ml. Indirect immunofluor- 
escence confirmed the presence of the virus in tonsils of 
some of the foxes. The polymerase chain reaction 
allowed the detection of VVTGgRAB in the tonsils of 
both of two foxes tested after 24 h, three of three foxes 
after 48 h, in the buccal mucosa of one of two foxes 
tested after 24 h and two of three foxes after 48 h and in 
the soft palate of one of two foxes tested after 24 h and 
one of three foxes after 48 h. VV was detected in the 
tonsils of one fox tested after 48 h, in the buccal 
mucosa of another fox tested after 24 h, and in the first 
fox after 48 h by the same reaction. Foxes were 
inoculated with virus isolated from fox tonsils 24 h 
after oral administration (with or without cell culture 
amplification) to perform back passages. No virus 
could be isolated in either case after this passage. The 
innocuity of VVTGgRAB was also demonstrated when 
foxes were inoculated with passaged virus. 
Introduction 
Sylvan rabies remains a disease of major importance in 
many parts of the world. The red fox (Vulpes vulpes) is 
currently the major vector of the disease in western 
Europe whereas triped skunks (Mephitis mephitis) and 
raccoons (Procyon lotor) are the main vectors of the 
disease in North America. For the last 25 years, most of 
the research on the control of sylvan rabies has been 
focused on the development of wildlife vaccination by 
the oral route. Vaccination campaigns carried out in 
several European countries with an attenuated strain of 
the rabies virus have shown the feasibility of the method 
(Steck et al., 1982; Schneider & Cox, 1983; Pastoret et 
al., 1987; Brochier et al., 1988a). However the use of 
these conventional rabies vaccines remains controversial 
because they are still pathogenic for laboratory and wild 
rodents (Wandeler et al., 1972; Schneider & Cox, 1983; 
Leblois & Flamand, 1988) and are heat-sensitive. 
Further technical developments are needed. A recom- 
binant virus (VVTGgRAB-26D3 187XP strain) derived 
from vaccinia virus (VV; Copenhagen strain) expressing 
the immunizing rabies virus glycoprotein has been 
developed by genetic engineering (Kieny et al., 1984). In 
this strain the cDNA corresponding to the glycoprotein 
of the ERA strain of rabies virus has been incorporated 
under the control of the 7.5K promoter into the 
thymidine kinase (TK) gene of VV. This virus 
(VVTGgRAB) was demonstrated to be effective for the 
oral immunization of foxes, raccoons and skunks, 
eliciting high titres of rabies virus-neutralizing antibo- 
dies and conferring long-term protection against rabies 
(Blancou et al., 1986; Rupprecht et al., 1986, 1988; 
Tolson et al., 1987, 1988; Brochier et al., 1988b). Oral 
administration of VVTGgRAB was shown to be 
perfectly safe for several domestic (Blancou et al., 1989; 
Soria Baltazar et al., 1987), laboratory (Wiktor et al., 
1988) and wildlife species (Brochier et al., 1989; 
Rupprecht et al., 1986, 1988; Tolson et al., 1987, 1988). 
Taking into account all the available xperimental data 
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concerning the efficacy and safety of this recombinant, a
preliminary restricted field trial of fox vaccination 
against rabies was carried out in 1987 in Belgium 
(Pastoret et al., 1988). Nothing was known about the 
multiplication site of this vaccine when administered 
orally in foxes, nor about the fate of the parental VV 
strain administered by the same route. Experiments were 
therefore designed to determine the multiplication site in 
foxes of the recombinant virus as compared with that of 
the parental strain of the virus, by virus isolation, 
titration and indirect immunofluorescence. The poly- 
merase chain reaction (PCR; Saiki et al., 1985) was also 
used to detect specific viral DNA in several fox organs. 
In this paper we also investigate the r covery of the virus 
from foxes after one passage with and without cell 
culture amplification. 
Methods  
Animals. Twenty-six foxes aged from 4 to 8 months, captured in a 
rabiesffree area in France, were used in this study. They were weighed, 
their sex was determined and they were divided into several 
experimental groups. 
Viruses. A live vaccinia (Copenhagen strain)--rabies glycoprotein 
(ERA strain) recombinant virus (VVTGgRAB-26D3 187XP strain) 
(Kieny et al., 1984) and the parental VV (Copenhagen strain) 
propagated in Veto cells were used for the inoculation at a titre of 108 
TCIDso per ml. 
Experimental protocol. In the first experiment nine animals were 
divided into two experimental groups (A and B). In group A, seven 
foxes were inoculated with 1 ml of recombinant virus. In group B, two 
foxes received 1ml of the VV Copenhagen strain. One control animal 
was given 1 ml of phosphate-buffered saline (PBS). VVTGgRAB, VV 
and PBS were administered directly into the oral cavity. Foxes were 
sacrificed at various times after vaccination by intra-cardiac injection 
of T61 (Hoechst Veterin~ir), after sedation with Hypnorm (0.1 ml/kg) 
(Janssen Pharmaceutica). The protocol of experiment 1 is shown in 
Table 1. 
In the second experiment, seven foxes were divided into two 
experimental groups (A and B). On day 0, the five foxes of group A 
were inoculated with 1 ml of VVTGgRAB and the two foxes of group B 
were inoculated with 1 ml of VV. One control fox was given 1 ml of 
PBS. The protocol of Experiment 2 is detailed in Table 2. Post-mortem 
examination was performed on all animals after euthanasia. 
In the third experiment, four foxes were inoculated with 
VVTGgRAB isolated from the tonsils of foxes during the first 
experiment. The titre of the inoculum was 104.3 TCIDso/ml. Two of 
them were sacrificed after 24 h and the remaining two were observed 
over 28 days, after which they were sacrificed and immediately 
necropsied. The same experiment was repeated with four other foxes 
inoculated with the same virus, previously amplified on Vero cell 
culture, at a titre of 1085 TCIDso/mL 
Sampling. Blood samples were collected from tbe jugular vein of foxes 
at the time of death, and faeces were removed at necropsy. The 
following organs were collected from each animal: brain, buccal 
mucosa, tonsils, spleen, parotid glands, maxillary glands, soft palate, 
retropharyngeal lymph nodes, submaxillary l mph nodes and mesen- 
teric lymph nodes. Samples of approximately 1 cm 3 were taken in 
triplicate, placed in individual Petri dishes and maintained at - 70 °C 
or placed in liquid nitrogen until used. 
Virus isolation and titration. Samples of each organ were placed in 
5 ml of Eagle's MEM containing gentamicin andground before being 
centrifuged for 15 rain at 1500 r.p.m. The supernatant (0.5 ml) was 
used for serial dilutions. Virus dilutions were inoculated into micro- 
wells simultaneously with a Veto cell suspension. After 5 days 
incubation, positive wells were counted, and virus titres were evaluated 
using Kfirber's methods (K/irber, 1931). 
Detection of viral antigens by indirect immunofluorescence. Samples of 
each tissue were mounted on tissue holders and cut with a microtome at 
a thickness of 3 to 5 ~tm. A minimum of 15 sections were cut for each 
sample and transferred to microscope slides covered with water 
containing albumin. Sections were fixed in acetone at - 20 °C for 2 h. 
Half the slides were stained using a rabbit anti-VV serum (dilution 
1:20) (Rh6ne-M6rieux) and a fluorescein isothiocyanate (FITC)- 
conjugated goat anti-rabbit IgG (dilution 1:40) (Flow Laboratories). 
The other half were stained using an anti-rabies glycoprotein 
monoclonai ntibody (dilution 1 : 1000) kindly supplied by Dr M. Lafon 
(Pasteur Institute, Paris, France) and an FITC-conjugated rabbit anti- 
mouse IgG (dilution 1:60) (Cappel Laboratories). Examination was 
performed using an epifluorescence microscope (Reichert, model 
'Polyvar'). 
Polymerase chain reaction 
Preparation of samples for PCR. DNA was prepared by deproteini- 
zation of tissue samples by overnight incubation with 2~ 2- 
mercaptoethanoi, 10 mM-Tris-HCl pH 8, 100 mM-NaCI, 10 mM- 
EDTA, pH 8, 0"5% SDS, and proteinase K (0-2mg/ml) digestion 
followed by three phenol-chloroform extractions as described pre- 
viously (Maniatis et al., 1982). DNA from each organ was then mixed 
with 50 t~l of TE buffer (10 mM-Tris-HC1 pH 7-5, 1 mM-EDTA) and 
DNA concentrations were estimated by measuring the absorbance 
ratio at 260/280 nm. 
Synthesis and purification of oligonueleotides. Two pairs of 
oligonucleotide primers chosen following sequence analysis of the VV 
TK gene (Weir & Moss, 1983) and the rabies virus glycoprotein gene 
(Anilionis et al., 1981) were synthesized on an automatic DNA 
synthesizer and purified by PAGE (Fig. 1). The first set (TK1 and 
TK2), with 24 bp of the TK gene of VV flanking the insert for the 
rabies virus glycoprotein, allowed the amplification of a 528 bp 
sequence of VV DNA and a 2347 bp sequence ofVVTGgRAB (Fig. 2). 
The other set (G 1 and G2), with 21 bp of the rabies virus glycoprotein 
gene was used for the amplification of a 621 bp sequence of 
VVTGgRAB DNA. 
DNA sequence amplification. Ten ~tg of DNA was amplified 
through two series of 35 PCR cycles. The reaction mixture consisted of 
l0 [.tl of a 10-fold concentrated reaction buffer containing 500 mM-KCI, 
100 mM-Tris-HCl pH 8, 15 mM-MgCl2, 0.1% gelatin, 200 ~tM of each of 
the four deoxynucleoside triphosphates (dATP, dCTP, dTTP, dGTP), 
0.4 ~tl of Taq polymerase (0-5 units/ml), 1p.g of each primer, water and 
DNA, to a total volume of 100 ~tl. The reaction mixture was covered 
with 50 p.l of mineral oil, to prevent evaporation. The amplification 
reaction was performed in a DNA thermal cycler (Perkin-Elmer/Ce- 
tus). The following conditions were found to be optimal: samples were 
first heated to 93 °C for 2-5 min, then submitted to 35 PCR cycles of 
1 min at 93 °C to denature the DNA, 2 min at 55 °C to allow annealing 
of the primers, and 5 to l0 rain at 72 °C to allow primer extension. A
final extension step was then performed for 10 min at 72 °C. Ten ~tl 
samples were then submitted to a second identical round of 35 PCR 
cycles. 
Detection of amplified products. The amplified products were 
detected by direct gel analysis (for controls) and by dot blot 
hybridization assay using labelled oligonucleotide probes (for controls 
and samples). For direct analysis, 10 ~tl of the reaction mixture was 
subjected to electrophoresis ona 1 to 1-5~ agarose gel and the DNA 
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was observed by u.v. fluorescence after staining with ethidium 
bromide. Mr markers were included in each gel. For dot blot analysis, 
30 Izl of the final product was adjusted to 0-4 M-NaOH, 0.25 mM-EDTA 
in a 200 btl volume, boiled for 2 min at 95 °C, cooled on ice, and 
immediately applied to a nylon filter membrane (GeneScreen Plus) by 
vacuum filtration using a Manifold I (Schleicher & Schiill). Wells were 
rinsed with 20 x SSPE (1 x SSPE is 0-18 M-NaC1, 10 mM-Na2HPO4- 
NaH2PO4, 1 mM-EDTA, pH 7-4), and the filters were then dried at 
room temperature. 
Oligonucleotide probes were labelled at their 5' end by phosphoryla- 
tion with 3zPqabelled ATP (sp. act. > 5000 Ci/mmol; Amersham) and 
T4 polynucleotide kinase (Amersham). The oligomers w re then 
purified on a 15% polyacrylamide/7 M-urea gel, which allows their 
separation from their precursors. The nylon membrane was prehybri- 
dized in a solution of 5 x SSPE, 5 x Denhardt's solution, 0.5% SDS 
for 1 h at the hybridization temperature (TK1, 29 °C; TK2, 33 °C) 
Approximately 100 ng of probe (2 x l06 c.p.m./ml) was then added and 
hybridization was allowed for 1 night at he same temperature. The 
filters were then rinsed twice in 2xSSPE, 0.1%SDS at room 
temperature, and once for 10min in 5 x SSPE containing 0-1% SDS at 
Tm - 1 °C. Finally, the filters were subjected to autoradiography at 
-70 °C (Fuji XR) for 4 h or 18 h. 
Results 
Virus isolation (experiments 1 and 3) 
As shown in Table 1, small amounts of virus (102 to 104.3 
TCIDso/ml) were recovered from the tonsils of five of 
the seven foxes inoculated with VVTGgRAB, during the 
first 48 h only. In group B, VV was detected in the tonsils 
of the animal sacrificed after 24 h. Virus was not 
detected (< 10 ~'5 TCID50/ml) in any other organ, serum 
or faeces of the vaccinated foxes, nor in any organ of the 
control animal. VVTGgRAB could not be isolated from 
foxes inoculated with viral stock recovered after one fox 
passage nor in foxes inoculated with the same viral stock 
amplified in cell culture. 
Indirect immunofluorescence (experiment 1)
As shown in Table 1, the indirect immunofluorescence 
test carried out with anti-VV rabbit polyclonal serum 
confirmed the presence of the virus in the tonsils of four 
of the five foxes from which VVTGgRAB had been 
isolated and in the fox from which VV was isolated. The 
indirect immunofluorescence test carried out with the 
anti-rabies glycoprotein monoclonal antibody confirmed 
the presence of virus in the tonsils of three of the five 
foxes from which the virus was re-isolated. Immuno- 
fluorescence was however too diffuse to allow precise 
localization of the virus in the tonsil. 
PCR results (experiment 2)
Determination of the sensitivity of the method 
Negative controls consisted of DNA from an uninfected 
fox. Positive controls were prepared with several 
dilutions of VVTGgRAB or VV in normal fox DNA;  the 
dilutions ranged from approximately one infectious 
particle per cell to one infectious particle per 106 cells. 
TK1 and TK2 oligonucleotides were used for the 
detection of VV and several combinations of oligo- 
nucleotide primers (TK1-TK2,  G1-G2,  TK1-G2,  G1-  
TK2), (Fig. 1) were used for the detection of 
VVTGgRAB. 
For each virus 10 ~1 of the amplified product of the 
10 -2 dilution (corresponding to 1 infectious particle/100 
cells) was detected by direct gel analysis (Fig. 2). For 
each virus 30 ~tl of the reaction mixture submitted to 
two series of 35 PCR cycles were detected by dot blot 
hybridization, up to and including the 10 -6 dilution (1 
infectious particle/million cells) (Fig. 3). No detectable 
amplification was observed in different samples of 
normal fox genomic DNA. 
Detection of VVTGgRAB in DNA of vaccinated foxes 
As shown in Table 2, using TK1-TK2 as primers and G1 
as the probe, VVTGgRAB was detected in the tonsils of 
two out of two inoculated foxes after 24 h and three of 
three foxes after 48 h, in the buccal mucosa of one of two 
foxes after 24 h and two of three foxes after 48 h and in 
the soft palate of one of two foxes after 24 h and one of 
three foxes after 48 h. No virus was detected from any 
other organ nor from any of the organs of the control fox. 
Detection of VV in DNA of vaccinated foxes 
After verification of the specificity of the amplified 
product in controls, we used TK I  and TK2 as primers 
and TK1 as probe. VV was detected in the tonsils of the 
inoculated fox tested after 48 h, and in the buccal mucosa 
of two other foxes, one tested after 24 h and the other 
after 48 h. Virus was not detected in any other organ. 
Discussion 
Many experiments have been carried out to demonstrate 
the efficacy and safety of the vaccinia-rabies glycopro- 
tein recombinant virus for vaccination against rabies. 
This vaccine could offer a suitable alternative to the use 
of attenuated strains of rabies virus used until now and 
has the advantage of good thermostability under field 
conditions. The parental Copenhagen strain of VV was 
associated with a limited number of human encephalitis 
complications in immunosuppressed people (Lane et al., 
1969). However previous experiments have demon- 
strated that the introduction of a foreign gene into the 
TK  gene of VV greatly reduces the virulence of this virus, 
even of neurovirulent strains (Buller et al., 1985). 
Furthermore no lesion was ever observed in immunosup- 
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(b) TKI ATG AAC GGC GGA CAT ATT CAG TTG 
TK2 TTA TGA GTC GAT CTA ACA CTT TCT 
G1 AAA TTC CCT ATT TAC ACG ATA 
G2 GCA ACT CTC ACT CCC TTT GGA 
Fig. 1. (a) The cDNA of the rabies glycoprotein gene under the control of a promoter (P) is inserted within the TK gene of the VV 
genome. Primers TK1 and TK2 are located on the TK gene and primers G1 and G2 are located on the glycoprotein gene. Numbers 
indicate the size (bp) of the different segments. (b) Sequence of synthetic oligonucleotide primers and complementary oligonucleotide 
probes. 
Tab le  1. Detection by viral solation and indirect immunofluorescence of VVTGgRAB and VV in tonsils of foxes vaccinated by 
the oral route 
Treatment 
VVTGgRAB VV PBS 
(Group A) (Group B) (Control) 
Fox no. 1 2 3 4 6 7 9 5 8 10 
Time of organ collection (h) 12 12 24 24 48 48 96 24 
Virus titre* - 102 104 102g 1043 102.8 - 104.3 
Detection of VV antigens by - - + + + + - + 
indirect immunofluorescence$ 
Detection of rabies glycoprotein by - -- + - + + - -- 
indirect immunofluorescence 
48 96 
* Virus titres are expressed as TCIDs0/ml. 
t (+),  Viral antigen detected; ( - ) ,  not detected. 
Tab le  2. Detection by PCR of VVTGgRAB or VV in orally vaccinated foxes 
Treatment 
VVTGgRAB VV PBS 
(Group A) (Group B) (Control) 
Fox no. 11 12 13 14 15 16 t7 18 
Time of organ collection (h) 24 24 48 48 48 24 48 24 
Tonsils + * + + + + - t + 
Buccal mucosa + - + - + + + 
Soft palate + - + . . . .  
Brain . . . . . . .  
Spleen . . . . . . .  
Parotid glands . . . . . . .  
Maxillary glands . . . . . . .  
Liver . . . . . . .  
Retropharyngeal lymph nodes . . . . . . .  
Submaxillary l mph nodes . . . . . . .  
Mesenteric lymph nodes . . . . . . .  
Blood . . . . . . .  
Faeces . . . . . . .  
* (+),  Viral DNA detected. 
t ( - ) ,  Viral DNA not detected. 
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Fig. 2. Electrophoretic gel analysis of PCR products of different 
dilutions of VVTGgRAB (lane 1, 2, 3, 4) or VV (lane 5, 6, 7, 8) in 
normal fox DNA. TK1 and TK2 were used asprimers. Lane M, size 
markers (bp) (HindlII-digested 2 DNA, HaelII-digested q~X174 RF 
DNA); lanes 1 and 5, 1 infectious particle/cell; lanes 2 and 6, 10 -1 
infectious particle/cell; lanes 3 and 7, 10 -2 infectious particle/cell; 
lanes 4 and 8, 10 -3 infectious particle/cell. 
1 2 3 4 5 6 7 
Fig. 3. Dot blot autoradiographofPCR products of ifferent dilutions 
of VVTGgRAB in normal fox DNA. Two series of 35 cycles were 
performed using TK1 and G2 as primers and G1 as probe. Lane 1, 
negative control; lane 2, 10 -1 infectious particle/cell; lane 3, 10 -2 
infectious particle/cell; lane 4, 10 -3 infectious particle/cell; lane5, 10 -4 
infectious particle/cell; lane 6, 10 -2 infectious particle/cell; lane 7, 10 -6 
infectious particle/cell. 
pressed nude mice inoculated with the VVTGgRAB by 
different routes (P. Desmettre, unpublished results). 
Nevertheless in preparation for a large scale release of 
the recombinant it is necessary to make a thorough study 
of the pathogenesis of this vaccine and to improve 
methods for detecting the virus. 
Using different techniques (virus isolation, indirect 
immunofluorescence and the very sensitive PCR 
method), virus (VVTGgRAB or VV) was detected 
during the first 48 h following vaccination by the oral 
route, but only in the tonsils, buccal mucosa and soft 
palate. Similar results have been obtained by others in 
raccoons (tonsils, parotid or submandibular lymph 
nodes, buccal mucosa) using virus isolation (Rupprecht 
et aL, 1988). The virus titres were very low in all cases, 
suggesting that if there is any viral multiplication, it must 
take place locally and at a very low level. 
To ascertain our PCR results, the sensitivity of the 
method was analysed. The limit of detection of the test in 
our experimental conditions was one infectious particle 
per 106 cells. On the other hand, as the organ samples 
contained 10 p.g of DNA, the DNA content of about 
1.5 x 106 cells, any negative result would indicate the 
absence of virus particles in the sample. 
Experiments carried out with VVTGgRAB adminis- 
tered into foxes' stomachs and to skunks intraduodenally 
(Tolson et al., 1987, 1988) showed that a reduced rate of 
seroconversion a d lower rabies virus-neutralizing anti- 
body titres were obtained by those routes. Furthermore, 
results of other experiments demonstrate hat tonsillec- 
tomy of the foxes does not affect he protection conferred 
by vaccination with VVTGgRAB (I. Thomas et al., 
unpublished results). All these data suggest hat orally 
administered recombinant virus multiplies at a low level 
within the oral cavity, in the tonsils and also in other 
tissues. Viraemia was never observed on days 0, 2, 3, 4, 5, 
6, 7, 8 and 14 in foxes inoculated with VVTGgRAB or 
VV (I. Thomas et al., unpublished results). No virus 
could be detected in salivary glands (parotid glands and 
maxillary glands) of foxes; the risk of transmission by 
saliva from one animal to another is therefore very low. 
This explains why transmission of the virus from 
vaccinated animals to unvaccinated controls was shown 
not to occur in foxes (one case) (Blancou et al., 1986; 
Tolson et al., 1988; Brochier et al., 1988c), in cats and 
dogs (Blancou et al., 1986) and in ferrets (Brochier et al., 
1989). However in raccoons, some unvaccinated animals 
held in contact with vaccinated ones had rabies virus- 
neutralizing antibodies and resisted challenge (Rup- 
precht et al., 1988). 
In our experiments no difference was observed in the 
replication sites of the recombinant virus as compared to 
the parental strain of VV, demonstrating that recombi- 
nation does not modify the tropism of VV. None of these 
viruses were detected in the brain, suggesting that the 
recombinant has no predilection for nerve cells. These 
results were consistent with those of other studies 
reporting the absence of detectable cytological abnorma- 
lities in cerebrospinal fluid from raccoons orally vaccina- 
ted with the recombinant virus (Hanlon et al., 1989). 
It is very important also to verify that the virus will not 
adapt o the fox and will not acquire some pathogenicity. 
In our experiments, virus was not detected in foxes 
inoculated with virus isolated after one passage, nor in 
others inoculated with the same virus after cell culture 
amplification. However, further experiments should be 
carried out with a higher number of animals to avoid any 
misinterpretation due to individual variations. In any 
case, neither lesions nor clinical signs were detected in 
animals vaccinated with these viruses during a 28-day 
observation period. 
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The fact hat the recombinant virus multiplies only in 
restricted sites minimizes the eventual risk of recombina- 
tion with other orthopoxviruses, bearing in mind that 
there is no known reservoir of VV in the wild. 
All these results represent additional arguments in 
favour of the use of the recombinant virus in the field. 
However even if risks appear to be very unlikely it is 
important o be cautious. In this respect, the PCR 
technique will be a useful tool for safety controls in field 
trials because of its very high sensitivity and specificity. 
Even in samples with a very low viral titre, the presence 
of the virus was detected. This technique should 
therefore permit he detection of the recombinant virus 
in any animal collected in a vaccinated area, suspected of
carrying a pox lesion. 
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